COMET Holding AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0360826991
CHF
212.40
75.4 (55.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About COMET Holding AG stock-summary
stock-summary
COMET Holding AG
Pharmaceuticals & Biotechnology
Comet Holding AG is a Switzerland-based manufacturer of systems and components for the non-destructive testing, security applications, and plasma excitation in the fabrication of memory chips, flat screens and solar panels. The Company is organized, along with its subsidiaries, into two segments: the Modules & Components segment develops, manufactures and markets components and modules for industrial x-ray applications, and components and radio frequency (RF) modules for a range of applications in vacuum capacitors and for semiconductor fabrication plants, and the Systems segment is a vendor of systems and services for non-destructive testing, using x-ray technology and computed tomography. The Company operates through its subsidiaries in Switzerland, Germany, Denmark, the United States, China and Japan.
Company Coordinates stock-summary
Company Details
Herrengasse 10 , WUENNEWIL-FLAMATT None : 3175
stock-summary
Tel: 41 31 744900041 31 7449996
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Heinz Kundert
Chairman of the Board of Directors, Interim Chief Executive Officer
Mr. Rolf Huber
Non-Executive Vice Chairman of the Board of Directors
Prof. Dr. Gian-Luca Bona
Non-Executive Member of the Board of Directors
Dr. Mariel Hoch
Non-Executive Member of the Board of Directors
Mr. Patrick Jany
Non-Executive Member of the Board of Directors
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 1,639 Million ()

stock-summary
P/E

40.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.71%

stock-summary
Debt Equity

-0.09

stock-summary
Return on Equity

12.10%

stock-summary
Price to Book

5.32